[1] Attard G, Parker C, Eeles RA, Schröder F, Tomlins SA, Tannock I,et al. Prostate cancer. Lancet. 2016; 387:70-82.
[2] Discacciati A, Orsini N, Wolk A. Body mass index and incidence of localized and advanced prostate cancer--a dose-response meta-analysis of prospective studies. Ann Oncol. 2012; 23:1665-1671.
[3] Bhindi B, Locke J, Alibhai SMH, Kulkarni GS, Margel DS, Hamilton RJ, et al. Dissecting the association between metabolic syndrome and prostate cancer risk: analysis of a large clinical cohort. Eur Urol. 2015; 67:64-70.
[4] Moller H, Roswall N, Van Hemelrijck M, Larsen SB, Cuzick J, Holmberg L, ,et al. Prostate cancer incidence, clinical stage and survival in relation to obesity: a prospective cohort study in Denmark. Int J Cancer. 2015;136:1940-1947.
[5] Lavalette C, Tretarre B, Rebillard X, Lamy PJ, Cenee S, Menegaux F. Abdominal obesity and prostate cancer risk: epidemiological evidence from the EPICAP study. Oncotarget. 2018; 9:34485-34494.
[6] Cao Y, Ma J. Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis. Cancer Prev Res (Phila) 2011; 4:486-501.
[7] Choi YJ, Lee DH, Han KD, Yoon H, Shin CM, Park YS, et al. Is nonalcoholic fatty liver disease associated with the development of prostate cancer? A nationwide study with 10,516,985 Korean men. PLoS One. 2018;13:e0201308.
[8] Choi WM, Lee JH, Yoon JH, Kwak C, LeeYJ, Cho YY, et al. Nonalcoholic fatty liver disease is a negative risk factor for prostate cancer recurrence. Endocr Relat Cancer. 2014; 21(2):343-353.
[9] Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008; 26:1148-1159.
[10] Fan JG, Jia JD, Li YM, Wang BY, Lu LG, Shi JP, et al. Guidelines for the diagnosis and management of nonalcoholic fatty liver disease: update 2010. J Dig Dis. 2011;12:38-44.
[11] VanWagner LB, Wilcox JE, Colangelo LA, Lloyd-Jones DM, Carr JJ, Lima JA, et al. Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: A population-based study. Hepatology. 2015; 62:773-783.
[12] Fanning DM , Kay E , Fan Y , Fitzpatrick JM, Watson RW. Prostate cancer grading: The effect of stratification of needle biopsy Gleason Score 4 + 3 as high or intermediate grade. BJU International. 2010; 105:631-635.
[13] Younossi ZM. Non-alcoholic fatty liver disease-A global public health perspective. J Hepatol. 2019;70:531-544.
[14] Ma J, Hwang SJ, Pedley A, Massaro JM, Hoffmann U, Chung RT, et al. Bi-directional analysis between fatty liver and cardiovascular disease risk factors. J Hepatol. 2017; 66:390-397.
[15] De Nunzio C, Truscelli G, Trucchi A, Petta S, Tubaro M, Gacci M, et al. Metabolic abnormalities linked to an increased cardiovascular risk are associated with high-grade prostate cancer: a single biopsy cohort analysis. Prostate Cancer Prostatic Dis. 2016; 19:35-39.
[16] Bhindi B, Xie WY, Kulkarni GS, Hamilton RJ, Nesbitt M, Finelli A, et al. Influence of Metabolic Syndrome on Prostate Cancer Stage, Grade, and Overall Recurrence Risk in Men Undergoing Radical Prostatectomy. Urology. 2016; 93:77-85.
[17] Wang LS, Murphy CT, Ruth K, Zaorsky NG, Smaldone MC, Sobczak ML, et al. Impact of obesity on outcomes after definitive dose-escalated intensity-modulated radiotherapy for localized prostate cancer. Cancer. 2015; 121:3010-3017.
[18] McDonald AM, Fiveash JB, Kirkland RS, Cardan RA, Jacob R, Kim RY, et al. Subcutaneous adipose tissue characteristics and the risk of biochemical recurrence in men with high-risk prostate cancer. Urol Oncol. 2017; 35:663.e15-663.e21.
[19] Ohwaki K, Endo F, Hattori K. Abdominal obesity, hypertension, antihypertensive medication use and biochemical recurrence of prostate cancer after radical prostatectomy. Eur J Cancer. 2015; 51:604-609.
[20] Nik-Ahd F, Howard LE, Eisenberg AT, Aronson WJ, Terris MK, Cooperberg MR, et al. Poorly controlled diabetes increases the risk of metastases and castration-resistant prostate cancer in men undergoing radical prostatectomy: Results from the SEARCH database. Cancer. 2019; 125:2861-2867.
[21] Beebe-Dimmer JL, Nock NL, Neslund-Dudas C, Rundle A, Bock CH, Tang D, et al. Racial differences in risk of prostate cancer associated with metabolic syndrome. Urology. 2009; 74:185-190.
[22] Zhang GM, Zhu Y, Dong DH, Han CT, Gu CY, Gu WJ, et al. The association between metabolic syndrome and advanced prostate cancer in Chinese patients receiving radical prostatectomy. Asian J Androl. 2015;17:839-844.
[23] Jeon KP, Jeong TY, Lee SY, Hwang SW, Shin JH, Kim DS. Prostate cancer in patients with metabolic syndrome is associated with low grade Gleason score when diagnosed on biopsy. Korean J Urol. 2012; 53:593-597.
[24] Petäjä EM, Yki-Järvinen H. Definitions of Normal Liver Fat and the Association of Insulin Sensitivity with Acquired and Genetic NAFLD-A Systematic Review. Int J Mol Sci. 2016;17: pii: E633.
[25] Gucalp A, Iyengar NM, Zhou XK, Giri DD, Falcone DJ, Wang H, et al. Periprostatic adipose inflammation is associated with high-grade prostate cancer. Prostate Cancer Prostatic Dis. 2017; 20:418-423.
[26] Lehrer S, Diamond EJ, Stagger S, Stone NN, Stock RG. Increased serum insulin associated with increased risk of prostate cancer recurrence. Prostate. 2002; 50:1-3.
[27] Di Sebastiano KM, Pinthus JH, Duivenvoorden WCM, Mourtzakis M. Glucose impairments and insulin resistance in prostate cancer: the role of obesity, nutrition and exercise. Obes Rev. 2018; 19:1008-1016.
[28] Fan JG , Peng YD. Metabolic syndrome and non-alcoholic fatty liver disease: Asian definitions and Asian studies. Hepatobiliary Pancreat Dis Int. 2007; 6:572-578.
[29] Wang X, Liu Z, Wang K, Wang Z, Sun X, Zhong L, et al. Additive Effects of the Risk Alleles of PNPLA3 and TM6SF2 on Non-alcoholic Fatty Liver Disease (NAFLD) in a Chinese Population. Frontiers in Genetics. 2016; 7:140.